Ortho Clinical Diagnostics announced that its ORTHO VISION Platform of fully automated blood analyzers for low-, mid- and high-volume transfusion medicine laboratories has received approval by the CFDA. The platform is now officially commercially available in China.
The ORTHO VISION Platform is comprised of analyzers that test blood for compatibility, ensuring transfusion patients receive the right type of blood. The ORTHO VISION Max was developed for mid- to high-volume labs, and it also supports more complex immunohematology testing, such as serial dilutions for titration studies, reflex tests, and selected cell antibody identification. The ORTHO VISION was developed for mid-volume labs.
As far as innovation goes, the ORTHO VISION platform has received a string of accolades for its ability to innovate in the field of transfusion medicine. Earlier this year, the ORTHO VISION Platform was recognized with an Edison™ Award for Innovation. It also received a 2016 Innovation Award from members of Premier, Inc., a healthcare improvement company that unites an alliance of approximately 3,600 U.S. hospitals and 120,000 other providers around the goal of transforming health care, and a Global Business Excellence 2017 Award for Product Innovation.
About China Med Device, LLC (CMD): CMD provides turn-key solution for Western medtech companies with regulatory and commercialization services. CMD helps its clients accelerate China entry and growth by offering: market Intelligence and research; CFDA regulatory services (premarket submission, clinical evaluation, clinical trial design & management, post market compliance and legal representation), and other commercial services. If you have an inquiry or feedback regarding our services please email us at info@ChinaMedDevice.com.